Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.

Median OS in this real-world study cohort was approximately 30 months following the diagnosis of MBC and worse for those receiving 1st LoT chemotherapy (23 months) than for those receiving endocrine (with or without targeted) therapy (32 months), although this difference did not reach statistical significance in our study.

also in 111,027 other papers

Moreover, it suggests that there may be significant benefits if endocrine therapy was used more frequently and earlier for patients with more aggressive HR+/HER2- MBC.

also in 13,097 other papers